|
Patent landscape, scope, and claims: |
Analysis of United States Patent 5,646,180: Claims, Scope, and Landscape
Patent US 5,646,180, titled "Therapeutic Methods Using Selective Serotonin Reuptake Inhibitors," was granted to SmithKline Beecham Corporation on July 8, 1997. This patent describes methods for treating depression using specific dosages of sertraline hydrochloride. The claims define the patented method, and the patent landscape indicates competition and potential for litigation within the antidepressant market.
What Is the Core Invention Claimed in US 5,646,180?
The central claim of US 5,646,180 is a method for treating depression.
Method of Treatment Claim
Claim 1 of US 5,646,180 defines the specific therapeutic method: "A method for the treatment of depression in a mammalian patient which comprises administering to said patient an effective amount of sertraline, wherein said effective amount is from about 50 mg to about 200 mg of sertraline hydrochloride per day."
- Active Ingredient: Sertraline hydrochloride.
- Indication: Treatment of depression.
- Dosage Range: Approximately 50 mg to 200 mg of sertraline hydrochloride per day.
This claim is product-by-method in nature, as it claims a method of using a known compound (sertraline) for a specific therapeutic purpose within a defined dosage range.
Dependent Claims
The patent also includes dependent claims that further refine the method:
- Claim 2: Specifies the dosage is administered once daily.
- Claim 3: Specifies the dosage is from about 50 mg to about 150 mg of sertraline hydrochloride per day.
- Claim 4: Specifies the dosage is from about 50 mg to about 100 mg of sertraline hydrochloride per day.
- Claim 5: Specifies the dosage is about 50 mg of sertraline hydrochloride per day.
- Claim 6: Specifies the dosage is about 100 mg of sertraline hydrochloride per day.
- Claim 7: Specifies the dosage is about 150 mg of sertraline hydrochloride per day.
- Claim 8: Specifies the dosage is about 200 mg of sertraline hydrochloride per day.
- Claim 9: Defines "depression" as major depressive disorder.
- Claim 10: Defines "depression" as dysthymic disorder.
These dependent claims aim to capture specific, potentially narrower therapeutic applications or preferred dosing regimens.
What Is the Scope of Protection Afforded by US 5,646,180?
The scope of US 5,646,180 is focused on the method of using sertraline hydrochloride within a particular daily dosage range for treating depression. It does not claim the compound sertraline itself, nor does it claim a specific pharmaceutical composition or formulation, except as it relates to achieving the claimed dosage.
Key Scope Delineations
- Method vs. Composition: The patent protects the act of administering a specific amount of sertraline hydrochloride for treating depression. It does not prevent others from manufacturing or selling sertraline hydrochloride for other uses, or even for treating depression if they do not infringe the claimed dosage range or if the patent is no longer in force.
- Dosage Specificity: The core of the patent's enforceability rests on the specific daily dosage range claimed (50 mg to 200 mg). Any method that involves administering sertraline hydrochloride to treat depression outside this specified range would not directly infringe Claim 1.
- Indication Limitation: The patent is tied to the treatment of "depression," specifically including major depressive disorder and dysthymic disorder in its dependent claims.
What Is the Patent Landscape Surrounding US 5,646,180?
The patent landscape for US 5,646,180 is primarily defined by the patent's expiration date and the existence of other patents covering sertraline, its formulations, and methods of use. Sertraline is the active ingredient in Zoloft, originally developed by Pfizer. US 5,646,180 was assigned to SmithKline Beecham, which later merged with Pfizer. This suggests a strategic layering of intellectual property around the drug.
Key Landscape Elements
- Original Compound Patents: The initial patents covering the composition of matter for sertraline have long expired. These would have provided the broadest protection for the molecule itself.
- Formulation and Method-of-Use Patents: Pharmaceutical companies frequently file subsequent patents covering novel formulations, new indications, or specific methods of treatment to extend market exclusivity. US 5,646,180 is an example of a method-of-use patent.
- Generic Competition: Once method-of-use patents expire, or if they are successfully challenged, generic manufacturers can enter the market with their own versions of the drug, provided they do not infringe any remaining valid patents.
- Patent Litigation: The antidepressant market is a high-value area, and patent litigation is common. Companies often challenge the validity or enforceability of patents held by competitors. The existence of method-of-use patents like US 5,646,180 can delay or complicate generic entry.
Timeline and Expiration
United States Patent 5,646,180 was granted on July 8, 1997, with a term typically extending 20 years from the filing date. Assuming a filing date around 1996 (common for patents granted in 1997), the patent would have expired around 2016.
- Filing Date (Estimated): Approximately 1996.
- Grant Date: July 8, 1997.
- Expiration Date (Estimated): Approximately 2016.
The expiration of this patent removed the specific method-of-use protection for treating depression within the claimed dosage range, facilitating broader market access for sertraline under generic labels, provided other IP issues were resolved.
Assignee and Related Entities
The original assignee of US 5,646,180 was SmithKline Beecham Corporation. SmithKline Beecham later merged with Pfizer Inc. in 2000. Pfizer was the originator of Zoloft (sertraline). This indicates that intellectual property surrounding sertraline was managed and potentially consolidated across these entities.
Potential for Infringement
Post-expiration, the primary concern for market participants is whether their activities infringe any other valid and enforceable patents related to sertraline. This could include:
- Manufacturing processes: If a novel or patented process is used to synthesize sertraline.
- Specific formulations: If a patented drug delivery system or formulation is used.
- New indications: If the drug is being used to treat an indication for which a patent is still in force.
For US 5,646,180 specifically, its expiration means that using sertraline hydrochloride to treat depression in the 50-200 mg daily dosage range is no longer protected by this particular patent.
What Are the Implications for R&D and Investment?
The analysis of US 5,646,180 and its landscape has direct implications for research and development strategies and investment decisions in the pharmaceutical sector, particularly in the antidepressant market.
R&D Strategy Implications
- Identifying White Space: For companies developing new antidepressants, understanding expired method-of-use patents like US 5,646,180 highlights areas where patent protection has lapsed, but also where innovation has historically focused. This can inform the search for novel mechanisms of action or therapeutic targets beyond serotonin reuptake inhibition.
- Dosage Optimization: While this patent is expired, the detailed exploration of dosage ranges for sertraline underscores the importance of pharmaceutical companies in identifying and patenting optimal therapeutic windows. Future R&D efforts should consider how specific dosing regimens for new drug candidates can be differentiated and protected.
- Combination Therapies: The landscape suggests a pattern of layered IP. Future R&D might focus on novel combination therapies involving sertraline or other SSRIs, or on entirely new drug classes, to secure new patentable inventions.
Investment Decision Implications
- Generic Market Entry: For investors focused on generic pharmaceuticals, the expiration of method-of-use patents is a key signal for potential market entry. Understanding the precise expiry dates and the scope of these patents is crucial for timing and assessing risk.
- Biologics and Novel Mechanisms: The increasing complexity of the patent landscape for small molecules can steer investment towards biologics or drugs targeting novel pathways, where the IP landscape may be less crowded or offer different protection strategies.
- Litigation Risk Assessment: When considering investments in companies involved in generic drug manufacturing or development, understanding the history of patent litigation surrounding established drugs like sertraline is vital. This patent, and others like it, have historically been part of the complex legal battles that shape market exclusivity.
Key Takeaways
- Patent US 5,646,180 claims a method for treating depression using sertraline hydrochloride in daily dosages of approximately 50 mg to 200 mg.
- The patent does not claim the sertraline molecule itself but rather a specific method of its therapeutic use within a defined dosage range.
- The patent expired around 2016, removing its protection for the claimed method of use.
- The patent landscape for sertraline includes expired composition-of-matter patents and various method-of-use and formulation patents that have been managed by originator companies like Pfizer and SmithKline Beecham.
- The expiration of this patent has facilitated generic market entry for sertraline in the treatment of depression within the specified dosage range.
Frequently Asked Questions
- Can a company currently sell sertraline to treat depression? Yes, provided they do not infringe any other valid and unexpired patents related to sertraline, its formulations, or specific methods of treatment beyond the scope of US 5,646,180. The expired status of US 5,646,180 itself permits this method of use.
- Does US 5,646,180 protect new formulations of sertraline? No, US 5,646,180 specifically claims a method of treatment based on dosage. It does not claim specific pharmaceutical formulations or compositions, unless such formulations are inherently tied to achieving the claimed dosage in a specific manner.
- Who was the original owner of US 5,646,180? The original assignee was SmithKline Beecham Corporation.
- What is the significance of the dosage range in the patent claims? The specific dosage range of 50 mg to 200 mg per day is central to the patent's claims. Any method of treatment employing sertraline hydrochloride for depression outside this range would not directly infringe this patent.
- Are there any other patents that might prevent the sale of sertraline for depression treatment? Yes, while US 5,646,180 has expired, other patents relating to sertraline's synthesis, formulation, or use for different indications might still be in force and require careful evaluation before market entry.
Citations
[1] SmithKline Beecham Corporation. (1997). Therapeutic Methods Using Selective Serotonin Reuptake Inhibitors (US Patent No. 5,646,180). U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
